Amgen is trading 3.26% up at $439.99 after positive Phase 3 CROSSING trial results for Tezspire in eosinophilic esophagitis. - The study met its primary endpoints; nearly 70% of patients receiving the higher dose achieved remission at week 24. - Results were reported October 14 and cited in coverage of Amgen’s share rise. The supplied S&P 500 and Nasdaq readings were down, so broader market sentiment does not explain the gain.